INTRODUCTION {#sec1}
============

Urosepsis is an infectious process that is defined as inflammation of the upper urinary tract that causes bacteremia, leading to local and distant tissue destruction \[[@cit0001]\]. Within the population diagnosed with sepsis, 20 to 30% present with the focus of their infection in the genitourinary tract \[[@cit0002]\]. Obstructive uropathy is responsible for 78% of urosepsis, while urolithiasis causes 43% of obstructive uropathy in urosepsis \[[@cit0003]\].

Currently, urosepsis secondary to obstructive urolithiasis is considered to be a life-threatening emergency and it must be treated using dual therapy including broad-spectrum antibiotics and urgent surgical decompression \[[@cit0004]\]. It is associated with a high mortality rate, up to 19%, if decompression is not performed \[[@cit0005]\]. The European Urological Association guidelines recommend antibiotic treatment for several days before stone removal \[[@cit0006]\]. However, the appropriate waiting time before performing an active treatment such as endoscopic ureterolithotomy (URS) has not been established \[[@cit0005], [@cit0006]\].

We hypothesized that early ureteroscopic treatment during the initial hospitalization after stabilization is a safe treatment in patients with urosepsis secondary to ureterolithiasis.

MATERIAL AND METHODS {#sec2}
====================

Patient demographics {#sec2.1}
--------------------

Once approved by the local ethics committee, a pilot study was performed at our institution between November 2013 and September 2017. Patients admitted with urosepsis associated with ureteral calculi were asked to participate in this study. All the patients who volunteered to participate were randomized into two different groups: early ureteroscopic treatment (EUT), who received definitive treatment after 48 to 72 hours of stabilization (defined as no fever, tachypnea, or tachycardia) during the initial hospitalization; or deferred ureteroscopic treatment (DUT), who received definitive treatment during a second hospitalization at least 7 days after discharge. Urosepsis was defined as a positive urine or blood culture plus meeting two or more of the systemic inflammatory response syndrome (SIRS) criteria, as follows: body temperature higher than 38°C or lower than 36°C, heart rate higher than 90/min, hyperventilation as evidenced by respiratory rate higher than 20/min or PaCO~2~ lower than 32 mmHg, or a white blood cell count higher than 12,000 cells/µL or lower than 4,000/µL \[[@cit0007]\]. Urine and blood culture results were obtained for all patients at admission.

All the patients underwent decompression using a ureteral stent during the first 12 hours after admission. The APACHE II score was calculated at admission. Stone characteristics (side, location, and diameter), sex distribution, age, and time between admission and urinary drainage were recorded. Endoscopic treatment was performed using a semi-rigid ureteroscope. If there was retropulsion to the kidney, a flexible ureteroscope (Wolf Cobra) was utilized. No pressure system was used in any of these patients. Operating time and complications after the URS were recorded (e.g. fever, sepsis, ureteral injury) and using the Clavien-Dindo classification \[[@cit0008]\]. Total duration of hospitalization, antibiotic treatment, length of the ureteral stent, and complication rate were also compared. In the DHT group, we considered the initial hospitalization plus the readmission for definitive treatment as the total duration of hospitalization. Association between sepsis severity according to APACHE II score and complications was assessed.

Statistical analysis {#sec2.2}
--------------------

Statistical analysis was performed using Stata 12.0v. Categorical variables were compared using Fisher\'s exact test. Normal distribution was analyzed in continuous variables using the Schapiro-Wilk test. In normally distributed variables, we analyzed the homogeneity of the variance and the correspondence t-test was performed. The Kruskal-Wallis test was used for non-normally distributed variables. P values of \<0.05 were considered to be significant.

RESULTS {#sec3}
=======

During the study period, 81 patients were hospitalized for suspicion of sepsis secondary to ureteral calculi. Among them, 53 patients met the selection criteria, and 27 of these patients volunteered to participate in the study ([Figure 1](#f0001){ref-type="fig"}). One patient rejected the protocol after the randomization process and withdrew from the study. Thus, there were 13 patients in the EUT group and 13 patients in the DUT group. Mean age was 43 years (standard deviation \[SD\], 14.9 years) in the DUT group and 49 years (SD, 20.4 years) in the EUT group. Mean stone size was 6 mm (SD, 3 mm) in and 7 mm (SD, 4 mm) in the DUT and EUT groups, respectively. There were no differences in gender distribution, side of ureteral calculi, stone location, or APACHE II score. General characteristics of the population are described in [Table 1](#t0001){ref-type="table"}. Age, stone size, and time between admission and urinary drainage were also similar in both groups. At admission, seven patients (53.8%) from the EUT group and eight patients (61.5%) from the DUT group were managed in the intensive care unit. Ten patients (77%) in the EUT group and 11 patients (85%) in the DUT group had a positive blood culture at the admission ([Table 2](#t0002){ref-type="table"}). [Table 3](#t0003){ref-type="table"} describes the specific characteristic of every single patient in each group (APACHE II score, initial scheme of antibiotics and complications).

###### 

General characteristics of the population

                                            SHT group    DHT group    P value
  ----------------- ----------------------- ------------ ------------ ---------
  Female                                    8 (61.5%)    10 (76.9%)   
  Male                                      5 (38.5%)    3 (23.1%)    0.673
  Mean age                                  49.15        43.15        0.3993
  Mean APACHE II                            9.3          7.07         0.246
                    Side of lithiasis                                 
  Right side                                8 (61.54%)   5 (38.46%)   
  Left side                                 5 (38.46%)   8 (61.54%)   0.434
                    Location of lithiasis                             
  Proximal ureter                           6 (46.15%)   4 (30.77%)   
  Medium ureter                             1 (7.69%)    2 (15.38%)   
  Distal ureter                             6 (46.15%)   7 (53.85%)   0.751
  Mean stone size                           7.38 mm      6.07 mm      0.5342

###### 

Results of blood and urine cultures

                     Blood culture   Urine culture                                 
  ------------------ --------------- --------------- ---- ------- ---- ------ ---- -------
  E. coli            4               40              5    45.45   8    72.7   9    69.23
  S. agalactiae      --              0               --   0       2    18.2   --   0
  S. epidermidis     1               10              --   0       --   0      --   0
  P. mirabilis       1               10              1    9.1     --   0      1    7.69
  E. faecium         --              0               --   0       --   0      1    7.69
  E. fecaelis        --              0               --   0       --   0      1    7.69
  K. pneumoniae      --              0               --   0       --   0      1    7.69
  C. albicans        --              0               --   0       1    0      --   0
  Negative culture   4               40              5    45.45   --   9.1    --   0
  TOTAL              10                              11           11          13   

###### 

Specific characteristics of all patients

  Patient ID   Study Group   Gender   Age   Stone size   Stone location   APACHE II Score   Days between surgeries   Initial scheme of antibiotics   Operative time   Complications
  ------------ ------------- -------- ----- ------------ ---------------- ----------------- ------------------------ ------------------------------- ---------------- -----------------
  1            EUT           F        20    3            Distal           5                 Passed the stone         Ceftriaxone                     --               No
  2            EUT           M        47    4            Distal           5                 5                        Ceftriaxone                     45               No
  3            EUT           F        64    8            Distal           25                7                        Ceftriaxone + Amikacin          30               No
  4            EUT           F        43    6            Proximal         2                 4                        Ceftriaxone                     45               No
  5            EUT           F        47    4            Proximal         4                 4                        Ceftriaxone                     45               No
  6            EUT           M        17    4            Proximal         5                 4                        Ceftriaxone                     45               No
  7            EUT           M        55    17           Proximal         9                 5                        Ceftriaxone                     80               No
  8            EUT           M        86    10           Proximal         11                7                        Ceftriaxone                     30               No
  9            EUT           F        27    5            Distal           6                 9                        Imipenem                        15               No
  10           EUT           F        70    14           Medial           12                4                        Ceftriaxone                     50               Fever
  11           EUT           F        41    6            Distal           7                 8                        Ceftriaxone                     15               No
  12           EUT           M        52    11           Proximal         9                 7                        Ceftriaxone                     70               No
  13           EUT           F        70    4            Distal           21                3                        Piperacillin + Tazobactam       30               No
  14           DUT           F        53    10           Distal           7                 17                       Ceftriaxone + Amikacin          40               No
  15           DUT           F        41    7            Proximal         1                 28                       Ceftriaxone                     50               No
  16           DUT           M        33    3            Distal           5                 Passed the stone         Piperacillin + Tazobactam       30               No
  17           DUT           F        41    6            Proximal         10                15                       Ceftriaxone + Amikacin          60               Ureteral injury
  18           DUT           F        18    4            Medial           2                 13                       Ceftriaxone                     40               No
  19           DUT           F        32    3            Distal           3                 17                       Ceftriaxone + Amikacin          35               No
  20           DUT           F        44    9            Medial           2                 11                       Ceftriaxone + Amikacin          60               No
  21           DUT           F        32    4            Proximal         7                 9                        Ceftriaxone                     40               Pain post URS
  22           DUT           M        51    7            Distal           15                12                       Piperacillin + Tazobactam       30               No
  23           DUT           F        40    6            Distal           3                 Passed the stone         Ceftriaxone                     --               No
  24           DUT           F        40    5            Distal           1                 13                       Ceftriaxone                     30               No
  25           DUT           F        79    12           Proximal         15                19                       Piperacillin + Tazobactam       60               No
  26           DUT           M        57    3            Distal           21                Passed the stone         Ceftriaxone + Amikacin          --               No

![Flow chart of patients.](CEJU-72-1890-g001){#f0001}

Four patients (15.4%) passed their stone before undergoing endoscopic treatment (three in the DUT group and one in the EUT group). Among the patients who required surgery, 81.8% were treated with a semi-rigid ureteroscope only (ten patients in the EUT group and eight patients in the DUT group). Four patients were treated with a flexible ureteroscope (two patients in each group). All flexible procedures were performed with a 12/14 Fr ureteral access sheath.

Total duration of hospitalization and complications were similar between both groups ([Table 4](#t0004){ref-type="table"}). Among the 26 patients, three had complications. Two of them were in the DUT group, as follows: one ureteral injury that was managed with a postoperative JJ stent (Clavien-Dindo III) and one patient with post-operative uncomplicated renal colic (Clavien-Dindo I). One patient in the EUT group developed post-URS fever (Clavien-Dindo I). No patients died during this study. There was no association between highest APACHE II score (equal or more than 10) and complications (p = 0.21).

###### 

Outcomes between both groups

                                                SHT group   DHT group   P value
  --------------------------------------------- ----------- ----------- ---------
  Total length of stay (mean)                   8           7           0.326
  Mean days with JJ stent                       8.5         18.38       0.0009
  Total length of antibiotic treatment (days)   17.2        19.92       0.04
  Postoperative fever                           1           0           0.308
  Clavien I complications                       1           2           1.0

A statistically significant difference was found in the duration of antibiotics (p = 0.04) and total days with a double J catheter (p = 0.0009; [Table 4](#t0004){ref-type="table"}). Only one patient in the DUT group received a stent after ureteroscopic treatment while five patients in the EUT group received a stent after URS. These catheters were removed on an outpatient basis and the indwelling time of the catheter was factored into the analysis. No patient received a urethral catheter in any group.

DISCUSSION {#sec4}
==========

Urosepsis is a detrimental systemic response in the host, which develops from a complicated urinary tract infection (UTI), and it is associated with significant morbidity and mortality \[[@cit0009]\]. A complicated UTI is one that occurs in a patient with a structural or functional abnormality that prevents the flow of urine, and in this study, it was lithiasis \[[@cit0010]\]. Emergency drainage is a priority treatment in these patients, and the definitive treatment for lithiasis is performed thereafter. However, the length of wait time before definitive treatment is performed has not been defined \[[@cit0011]\].

For our study, we considered urosepsis to be all patients who had a positive urine or blood culture and who met two or more of the SIRS criteria. We did not exclude patients with a negative urine culture because a negative urine test does not rule out a UTI in the setting of complete obstruction where infected urine may not drain to the bladder \[[@cit0012]\]. Also, we did not exclude patients with a negative blood culture because sometimes blood cultures may not be positive in septic patients for several reasons such as infection by fastidious organisms, previous antimicrobial therapy, growth inhibitory factors in the blood, and sampling error \[[@cit0013]\]. Most of our patients in both groups (77% in EUT and 85% in DUT) had a positive blood culture result that was associated with bacteremia. Additionally, the use of two or more SIRS criteria to identify sepsis does not necessarily indicate a dysregulated and potentially life-threatening infection, but the new Sepsis-3 definitions are still not universally accepted and they are becoming controversial \[[@cit0014], [@cit0015]\]. We believe that the combination of the present criteria are a good selection tool to select populations within the scope of this study.

Yousef et al. previously compared the outcomes after ureteroscopic lithotripsy in patients who initially presented with urosepsis using a match-pair analysis. In their study, patients who initially presented with urosepsis were treated definitively after a median duration of 32 days \[[@cit0016]\]. In our study, the group of patients who received early treatment had a mean of 5.38 days since the initial drainage. Multiple studies have reported a reduced quality of life in patients with a ureteral catheter, with approximately 80% of patients reporting bothersome symptoms and side effects. The use of a ureteral catheter affects several aspects of daily life, and some of the symptoms reported by the patients include symptoms of the lower urinary tract, hematuria, sleep disorders, sexual function and desire, loss of work days, and anxiety \[[@cit0017], [@cit0018]\]. Performing early treatment of the lithiasis and achieving a significant reduction in the time with a catheter should be associated with a considerable reduction of the symptoms that are associated with its use, without an increase in associated complications. Thus, we consider that patients should be treated as soon as possible because a ureteral catheter is associated with a decrease in quality of life and bothersome symptoms such as frequency, urgency, dysuria, or flank pain \[[@cit0019]\].

Wang et al. recently showed that an immediate ureteroscopic treatment would be safe when performed by experienced surgeons. They did not find an increase in complications between immediate ureteroscopic management or percutaneous nephrostomy, although they described that emergent retrograde ureteroscopic management may lead to increased bacteremia because of the increase in body temperature \[[@cit0020]\]. In our study, we did not find statistically significant differences in morbidity or total length of hospitalization in patients who underwent early definitive treatment for lithiasis. Fever was not an important complication. In this scenario, we consider that early endoscopic treatment would be a safety option and it was not associated with an increased risk of bacteremia for the patient.

There are several limitations of our study. Half of the patients that met the selection criteria declined to participate in the study. This was a personal decision and it was not related to exclusion of severely ill patients that would lead to a selection bias in the study. It may be because of the patients\' fear of participating in clinical studies. We decided to perform the surgery using only the clinical criteria and with no blood test or other information related to the decision process. We believe that this is an easy and efficient way to determine the right time to perform the surgery. Since this is a pilot study there is a small number of patients included on it. With our results a larger, multi-center study is required to confirm our results.

To the best of our knowledge, there were no published studies that established a definite time for the definitive treatment that is used for ureteral calculus in septic patients who underwent previous drainage. We believe that it is important to develop more prospective studies with a larger number of patients, which can confirm our findings and perhaps establish other benefits or risks for early disease resolution.

CONCLUSIONS {#sec5}
===========

Early ureteroscopic management of ureteral stones is as safe as deferred treatment of patients admitted with urosepsis secondary to ureterolithiasis. Early ureteroscopic treatment is associated with a shorter period with a ureteral stent, which can potentially improve the patients\' quality of life and it is not associated to an increase in terms of complications.
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